Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.
Int J Biochem Cell Biol. 2011 Oct;43(10):1417-21. doi: 10.1016/j.biocel.2011.06.007. Epub 2011 Jun 17.
The search for new therapeutic strategies for prostate and breast cancer is of significant interest. Signal transducer and activator of transcription 5a/b (Stat5a/b) controls viability and growth of prostate cancer. Nuclear active Stat5a/b expression is clustered to high grade prostate cancers, predicts early disease recurrence and promotes metastatic dissemination of prostate cancer. In breast cancer, the role of Stat5a/b is more complex. In rodent model systems, Stat5a/b may promote malignant transformation and enhance growth of the breast tumors. In contrast, Stat5a/b activation in established human breast cancer positively correlates with tumor differentiation, prevents metastatic dissemination, and predicts favorable clinical outcome of node-negative breast cancer. Here we review the molecular structure and biological functions of Stat5a/b and discuss the potential applications of Stat5a/b for therapy development and as a prognostic marker for prostate and breast cancer.
寻找前列腺癌和乳腺癌的新治疗策略具有重要意义。信号转导子和转录激活子 5a/b（Stat5a/b）控制前列腺癌的存活和生长。核活性 Stat5a/b 表达与高级别前列腺癌聚集，预测早期疾病复发并促进前列腺癌的转移扩散。在乳腺癌中，Stat5a/b 的作用更为复杂。在啮齿动物模型系统中，Stat5a/b 可能促进恶性转化并增强乳腺肿瘤的生长。相比之下，在已建立的人类乳腺癌中，Stat5a/b 的激活与肿瘤分化呈正相关，可防止转移扩散，并预测淋巴结阴性乳腺癌的良好临床结局。本文综述了 Stat5a/b 的分子结构和生物学功能，并讨论了 Stat5a/b 在治疗开发和作为前列腺癌和乳腺癌的预后标志物方面的潜在应用。
